We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher (DHR) Shares Gain 11% in 3 Months: What's Driving It?
Read MoreHide Full Article
Shares of Danaher Corporation (DHR - Free Report) have gained notably in the past three months. A solid portfolio of products, healthy inorganic actions and strengthening demand seem to have boosted sentiments for the stock.
The Washington, DC-based company belongs to the Zacks Diversified Operations industry. The industry is in the top 28% (with a rank of 70) of more than 250 Zacks industries. Danaher has a $172.8-billion market capitalization and it currently carries a Zacks Rank #2 (Buy).
In the past three months, the company’s shares have gained 11% compared with the industry’s growth of 9%. Notably, the S&P 500 has risen 9.2% during the same period.
Image Source: Zacks Investment Research
Factors Influencing the Stock
In the past three months, Danaher delivered impressive results for the first quarter of 2021. Its earnings surpassed the Zacks Consensus Estimate by 50.9% and sales beat the same by 0.6%. The company anticipates sales, including the impact of Cytiva, to grow in the high-teen range in 2021 and the mid-20% in the second quarter.
A solid portfolio of products as well as a focus on innovation and an efficient workforce is expected to continue aiding Danaher in the quarters ahead. The pandemic has also been beneficial for the company, having boosted product demand by 20% year over year. Demand is expected to be strong for bioprocessing and non-bioprocessing products, molecular testing, and consumables. Notably, core sales are predicted to grow in low-double digits in the second quarter and high-single to low-double digits in 2021 due to the pandemic-induced demand.
Additionally, Danaher’s inorganic actions (including acquisitions and divestments) have been proving advantageous. Acquisitions and divestments had a net positive impact of 34.5% year over year on sales in the first quarter of 2021. Notably, Canada-based Vanrx Pharmasystems and Swift Biosciences were acquired by Danaher in the first quarter of 2021.
Currently, the Zacks Consensus Estimate for the company’s earnings is pegged at $8.91 for 2021 and $9.00 for 2022, marking an increase of 19.3% and 11.9% from the respective 60-day-ago figures. Also, the estimate for the second quarter improved from $1.76 to $2.04. Such an upward revision in earnings estimates is reflective of healthy operating conditions for the company.
Some other top-ranked stocks in the industry are Griffon Corporation (GFF - Free Report) , Macquarie Infrastructure Company and Crane Co. (CR - Free Report) . While Griffon currently sports a Zacks Rank #1 (Strong Buy), both Macquarie and Crane carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, earnings estimates for these stocks have improved for the current year. Further, earnings surprise for the last reported quarter was 50.00% for Griffon, 25.00% for Macquarie and 26.72% for Crane.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Image: Bigstock
Danaher (DHR) Shares Gain 11% in 3 Months: What's Driving It?
Shares of Danaher Corporation (DHR - Free Report) have gained notably in the past three months. A solid portfolio of products, healthy inorganic actions and strengthening demand seem to have boosted sentiments for the stock.
The Washington, DC-based company belongs to the Zacks Diversified Operations industry. The industry is in the top 28% (with a rank of 70) of more than 250 Zacks industries. Danaher has a $172.8-billion market capitalization and it currently carries a Zacks Rank #2 (Buy).
In the past three months, the company’s shares have gained 11% compared with the industry’s growth of 9%. Notably, the S&P 500 has risen 9.2% during the same period.
Factors Influencing the Stock
In the past three months, Danaher delivered impressive results for the first quarter of 2021. Its earnings surpassed the Zacks Consensus Estimate by 50.9% and sales beat the same by 0.6%. The company anticipates sales, including the impact of Cytiva, to grow in the high-teen range in 2021 and the mid-20% in the second quarter.
A solid portfolio of products as well as a focus on innovation and an efficient workforce is expected to continue aiding Danaher in the quarters ahead. The pandemic has also been beneficial for the company, having boosted product demand by 20% year over year. Demand is expected to be strong for bioprocessing and non-bioprocessing products, molecular testing, and consumables. Notably, core sales are predicted to grow in low-double digits in the second quarter and high-single to low-double digits in 2021 due to the pandemic-induced demand.
Additionally, Danaher’s inorganic actions (including acquisitions and divestments) have been proving advantageous. Acquisitions and divestments had a net positive impact of 34.5% year over year on sales in the first quarter of 2021. Notably, Canada-based Vanrx Pharmasystems and Swift Biosciences were acquired by Danaher in the first quarter of 2021.
Currently, the Zacks Consensus Estimate for the company’s earnings is pegged at $8.91 for 2021 and $9.00 for 2022, marking an increase of 19.3% and 11.9% from the respective 60-day-ago figures. Also, the estimate for the second quarter improved from $1.76 to $2.04. Such an upward revision in earnings estimates is reflective of healthy operating conditions for the company.
Danaher Corporation Price and Consensus
Danaher Corporation price-consensus-chart | Danaher Corporation Quote
Other Stocks to Consider
Some other top-ranked stocks in the industry are Griffon Corporation (GFF - Free Report) , Macquarie Infrastructure Company and Crane Co. (CR - Free Report) . While Griffon currently sports a Zacks Rank #1 (Strong Buy), both Macquarie and Crane carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, earnings estimates for these stocks have improved for the current year. Further, earnings surprise for the last reported quarter was 50.00% for Griffon, 25.00% for Macquarie and 26.72% for Crane.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>